BiotechTube
Infinity Bio

Infinity Bio

San Diego, United States· Est.
infinitybio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Infinity Bio is a private, early-revenue biotech service provider founded in 2019, specializing in large-scale antibody reactivity profiling. Its core technology, Molecular Indexing of Proteins by Self-Assembly (MIPSA), uses advanced DNA synthesis and sequencing to interrogate antibody repertoires against comprehensive, customizable antigen libraries. The company serves academic, biopharma, and government researchers, offering insights for infectious disease, autoimmune disorders, allergy research, cancer immunotherapy, and vaccine development. Infinity Bio operates primarily as a contract research service platform, providing data and bioinformatic analysis to accelerate client discoveries.

Infectious DiseasesAutoimmune DiseasesAllergyOncology

Technology Platform

Molecular Indexing of Proteins by Self-Assembly (MIPSA) - a high-throughput phage display platform using DNA synthesis and sequencing to decode antibody reactivities against comprehensive, customizable antigen libraries (peptides and full-length proteins).

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The growing demand for comprehensive immune profiling in precision medicine, vaccine development, and autoimmune disease research presents a significant market.
Infinity Bio's ability to offer fully custom antigen libraries allows it to address niche research needs and form strategic partnerships with large pharma, creating potential for recurring revenue and data licensing opportunities.

Risk Factors

The company faces competition from other high-throughput serological platforms and academic methods.
Its service-based model leads to project-driven revenue volatility and dependence on grant-funded academic clients.
Technological disruption or the development of in-house capabilities by large clients could threaten its market position.

Competitive Landscape

Infinity Bio competes in the high-dimensional serology space against other technology providers like peptide microarray companies (e.g., JPT Peptide Technologies) and academic methods like PhIP-Seq. Its key differentiators are the claimed comprehensiveness and customizability of its MIPSA libraries, its end-to-end service including bioinformatics, and its focus on epitope-resolution data. It also competes indirectly with traditional, low-plex immunoassays.

More companies in United States →